Brainstorm Cell (BCLI) ALS Trial Results 'Robust' - Maxim Group

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Brainstorm Cell (BCLI) ALS Trial Results 'Robust' - Maxim Group

BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS)

July 18, 2016 8:01 AM EDT

HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn® in Patients with ALS. The study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated.  NurOwn also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit.  Notably, response rates were higher for NurOwn-treated subjects compared to placebo at all... More